Pharmacogenomic aspects of bipolar disorder: An update. Budde, M., Degner, D., Brockmöller, J., & Schulze, T. G. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology, 27(6):599–609, June, 2017. doi abstract bibtex The hopes for readily implementable precision medicine are high. For many complex disorders, such as bipolar disorder, these hopes critically hinge on tangible successes in pharmacogenetics of treatment response or susceptibility to adverse events. In this article, we review the current state of pharmacogenomics of bipolar disorder including latest results from candidate genes and genome-wide association studies. The majority of studies focus on response to lithium treatment. Although a host of genes has been studied, hardly any replicated findings have emerged so far. Very small samples sizes and heterogeneous phenotype definition may be considered the major impediments to success in this field. Drawing from current experiences and successes in studies on diagnostic psychiatric phenotypes, we suggest several approaches for our way forward.
@article{budde2017,
title = {Pharmacogenomic aspects of bipolar disorder: {An} update},
volume = {27},
issn = {1873-7862},
shorttitle = {Pharmacogenomic aspects of bipolar disorder},
doi = {10.1016/j.euroneuro.2017.02.001},
abstract = {The hopes for readily implementable precision medicine are high. For many complex disorders, such as bipolar disorder, these hopes critically hinge on tangible successes in pharmacogenetics of treatment response or susceptibility to adverse events. In this article, we review the current state of pharmacogenomics of bipolar disorder including latest results from candidate genes and genome-wide association studies. The majority of studies focus on response to lithium treatment. Although a host of genes has been studied, hardly any replicated findings have emerged so far. Very small samples sizes and heterogeneous phenotype definition may be considered the major impediments to success in this field. Drawing from current experiences and successes in studies on diagnostic psychiatric phenotypes, we suggest several approaches for our way forward.},
language = {eng},
number = {6},
journal = {European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology},
author = {Budde, M. and Degner, D. and Brockmöller, J. and Schulze, T. G.},
month = jun,
year = {2017},
pmid = {28342679},
keywords = {Humans, Bipolar Disorder, Pharmacogenetics, Lithium, Case-Control Studies, Genetics, Antipsychotic Agents, Manic-depressive illness, Mood disorders, Mood stabilizers, Personalized medicine},
pages = {599--609},
}
Downloads: 0
{"_id":"EHYmuNpbKtCTvsycq","bibbaseid":"budde-degner-brockmller-schulze-pharmacogenomicaspectsofbipolardisorderanupdate-2017","author_short":["Budde, M.","Degner, D.","Brockmöller, J.","Schulze, T. G."],"bibdata":{"bibtype":"article","type":"article","title":"Pharmacogenomic aspects of bipolar disorder: An update","volume":"27","issn":"1873-7862","shorttitle":"Pharmacogenomic aspects of bipolar disorder","doi":"10.1016/j.euroneuro.2017.02.001","abstract":"The hopes for readily implementable precision medicine are high. For many complex disorders, such as bipolar disorder, these hopes critically hinge on tangible successes in pharmacogenetics of treatment response or susceptibility to adverse events. In this article, we review the current state of pharmacogenomics of bipolar disorder including latest results from candidate genes and genome-wide association studies. The majority of studies focus on response to lithium treatment. Although a host of genes has been studied, hardly any replicated findings have emerged so far. Very small samples sizes and heterogeneous phenotype definition may be considered the major impediments to success in this field. Drawing from current experiences and successes in studies on diagnostic psychiatric phenotypes, we suggest several approaches for our way forward.","language":"eng","number":"6","journal":"European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology","author":[{"propositions":[],"lastnames":["Budde"],"firstnames":["M."],"suffixes":[]},{"propositions":[],"lastnames":["Degner"],"firstnames":["D."],"suffixes":[]},{"propositions":[],"lastnames":["Brockmöller"],"firstnames":["J."],"suffixes":[]},{"propositions":[],"lastnames":["Schulze"],"firstnames":["T.","G."],"suffixes":[]}],"month":"June","year":"2017","pmid":"28342679","keywords":"Humans, Bipolar Disorder, Pharmacogenetics, Lithium, Case-Control Studies, Genetics, Antipsychotic Agents, Manic-depressive illness, Mood disorders, Mood stabilizers, Personalized medicine","pages":"599–609","bibtex":"@article{budde2017,\n\ttitle = {Pharmacogenomic aspects of bipolar disorder: {An} update},\n\tvolume = {27},\n\tissn = {1873-7862},\n\tshorttitle = {Pharmacogenomic aspects of bipolar disorder},\n\tdoi = {10.1016/j.euroneuro.2017.02.001},\n\tabstract = {The hopes for readily implementable precision medicine are high. For many complex disorders, such as bipolar disorder, these hopes critically hinge on tangible successes in pharmacogenetics of treatment response or susceptibility to adverse events. In this article, we review the current state of pharmacogenomics of bipolar disorder including latest results from candidate genes and genome-wide association studies. The majority of studies focus on response to lithium treatment. Although a host of genes has been studied, hardly any replicated findings have emerged so far. Very small samples sizes and heterogeneous phenotype definition may be considered the major impediments to success in this field. Drawing from current experiences and successes in studies on diagnostic psychiatric phenotypes, we suggest several approaches for our way forward.},\n\tlanguage = {eng},\n\tnumber = {6},\n\tjournal = {European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology},\n\tauthor = {Budde, M. and Degner, D. and Brockmöller, J. and Schulze, T. G.},\n\tmonth = jun,\n\tyear = {2017},\n\tpmid = {28342679},\n\tkeywords = {Humans, Bipolar Disorder, Pharmacogenetics, Lithium, Case-Control Studies, Genetics, Antipsychotic Agents, Manic-depressive illness, Mood disorders, Mood stabilizers, Personalized medicine},\n\tpages = {599--609},\n}\n\n","author_short":["Budde, M.","Degner, D.","Brockmöller, J.","Schulze, T. G."],"bibbaseid":"budde-degner-brockmller-schulze-pharmacogenomicaspectsofbipolardisorderanupdate-2017","role":"author","urls":{},"keyword":["Humans","Bipolar Disorder","Pharmacogenetics","Lithium","Case-Control Studies","Genetics","Antipsychotic Agents","Manic-depressive illness","Mood disorders","Mood stabilizers","Personalized medicine"],"metadata":{"authorlinks":{}},"downloads":0},"bibtype":"article","biburl":"https://bibbase.org/f/8yBxW5neHauDryu9w/LCNeuro Site.bib","dataSources":["ZHHpjMFTPYP8NqJif"],"keywords":["humans","bipolar disorder","pharmacogenetics","lithium","case-control studies","genetics","antipsychotic agents","manic-depressive illness","mood disorders","mood stabilizers","personalized medicine"],"search_terms":["pharmacogenomic","aspects","bipolar","disorder","update","budde","degner","brockmöller","schulze"],"title":"Pharmacogenomic aspects of bipolar disorder: An update","year":2017}